Samjin Pharmaceuticals Co., Ltd. (KRX:005500)

Market Cap	217.07B
Revenue (ttm)	274.03B
Net Income (ttm)	21.89B
Shares Out	12.26M
EPS (ttm)	1,727.82
PE Ratio	10.24
Forward PE	n/a
Dividend	800.00 (4.52%)
Ex-Dividend Date	Dec 27, 2024

Volume	19,189
Average Volume	25,093
Open	17,830
Previous Close	17,770
Day's Range	17,570 - 17,830
52-Week Range	16,690 - 21,500
Beta	0.25
RSI	51.64
Earnings Date	Feb 18, 2025

About Samjin Pharmaceuticals

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clin...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 586
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 005500

Financial Performance

In 2022, Samjin Pharmaceuticals's revenue was 274.03 billion, an increase of 9.58% compared to the previous year's 250.07 billion. Earnings were 21.89 billion, a decrease of -22.92%.